The Latest Breaking News from Sanofi

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Teva stock tumbled Wednesday after the company announced it would partner with Sanofi to develop an inflammatory bowel disease treatment.

Moderna said Wednesday its flu shot outperformed broadly used vaccines from Sanofi and GSK. The results bolstered Moderna stock.

The pharmaceutical sector is expanding due to advanced technologies such as AI and new drug discoveries. Hence, quality pharma stocks GoodRx Holdings (GDRX), Merck & Co. (MRK), and Sanofi (SNY) might be profitable investments right now. Read on.

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

Data intelligence platform, Tracer, announced a new president to lead the company

Big Pharma has a problem, and buying up biotech companies helps solve it. But the FTC has its own ideas about industry mergers. Here's where things stand.

Knowing how to use and implement generative A.I. will be a “minimum expectation” for future CEOs, Sanofi CEO Paul Hudson said.

StemCures, a medical clinic in Ohio focused on stem cell therapy, will be establishing a manufacturing lab in Telangana with around $54 million investment and employment potential for around 150 people.